New game
Download
Get Academic Plan
Share game
Integrate it into your platform

You can integrate the game into an LMS compatible with LTI 1.1 or LTI 1.3 such as Canvas, Moodle, or Blackboard. This way, the scores will be automatically saved into the platform’s gradebook.
Download
You have exceeded the maximum number of games you can integrate into Google Classroom with your current Plan.

To integrate as many games as you want in Google Classroom, you need an Academic Plan or a Commercial Plan.

You have exceeded the maximum number of games you can integrate into Microsoft Teams with your current Plan.

To integrate as many games as you want in Microsoft Teams, you need an Academic Plan or a Commercial Plan.

Downloading games is an exclusive feature for users with an Academic Plan or a Commercial Plan.

Get your Academic Plan or your Commercial Plan now and start integrating your games into your LMS, website or blog.

If you wish, you can download a demo game here and test its integration:

CONSORT RCT Quick Quiz

Yes or No

Played 0

About this activity

Yes/No questions on CONSORT for RCTs

Created by

India

Download the paper version to play

Make your own free game from our game creator
Compete against your friends to see who gets the best score in this game

Top Games

%
Anonymous
Anonymous
%
%
%
You have exceeded the maximum number of games you can print with your current Plan.

To print as many games as you want, you need an Academic Plan or a Commercial Plan.

Print your game
CONSORT RCT Quick Quiz
 

CONSORT RCT Quick QuizOnline version

Yes/No questions on CONSORT for RCTs

by Amit Jaiswal
1

Use the word “randomised” in the title

2

Specific objectives mentioned in the summary

3

Trial design (e.g., parallel group, cluster) and framework (e.g., superiority, equivalence, non- inferiority, exploratory) mentioned in the summary

4

Eligibility criteria for participants and settings where the trial was conducted mentioned in summary

5

Intervention(s) and comparator(s) intended for each group mentioned in the summary

6

Primary outcome(s) mentioned in the summary

7

How participants were allocated to interventions (e.g., centralized computer-generated randomization) mentioned in the summary

8

Who was blinded after assignment to interventions (e.g., participants, care providers, outcome assessors) mentioned in the summary

9

Number of participants randomized to each group mentioned in the summary

10

For the primary outcome, the number of participants analysed in each group, a result for each group and the estimated effect size and its precision is mentioned in the summary

11

General interpretation of the results mentioned ion the summary

12

Name of registry, Trial registry identifying number, URL to registry record, Date of registration mentioned

13

Where the protocol and full statistical analysis plan can be accessed with URL to its location mentioned

14

Sources of funding and other support, role of funders in the design, conduct, analysis and reporting of the trial mentioned

15

Financial and other conflicts of interest of the manuscript authors mentioned

16

Scientific background and rationale mentioned in the introduction

17

Specific objectives related to benefits and harms mentioned in the introduction

18

Description of trial design including type of trial (e.g., parallel group, crossover), allocation ratio, and framework (e.g., superiority, equivalence, non-inferiority etc.) mentioned in methodology

19

Important changes to the trial after it commenced including any outcomes or analyses that were not prespecified, with reason mentioned in methodoly

20

Settings (e.g., community, hospital) and locations (e.g., countries, sites) where the trial was conducted mentioned in methodology

21

Eligibility criteria for participants including method of recruitment of participants (eg. referral, self selection or advertisements) mentioned in methodology

22

Details of each intervention and comparator to allow replication eg. Components of the intervention and comparator, How, when and for how long they were administered etc. mentioned in methodology

23

Any physical or informational materials used as part of the intervention/comparator (e.g., instruction manual) and where the materials can be accessed mentioned in methodology

24

When the comparator group is “usual care”, Description of usual care and Whether the intervention group(s) also received usual care mentioned in methodology

25

Which outcomes are primary and secondary as prespecified in the protocol, Rationale for the choice of trial outcomes mentioned in the methodology and whether they are part of a core outcome set

26

How sample size was determined, including all assumptions (eg. statistical level of significance, statistical power etc.)supporting the sample size calculation mentioned in methodology

27

Explanation of any interim analyses and stopping guidelines mentioned in methodology

28

Who generated the random allocation sequence and the method used mentioned in methodology

29

Type of randomisation and details of any restriction mentioned in methodology(e.g., stratification, blocking and block size) mentioned in the methodology

30

Mechanism used to implement the random allocation sequence (e.g., central computer/telephone; sequentially numbered, sealed containers) mentioned in the menthodology

31

Who enrolled the participants and those who assigned participants to the interventions mentioned in methodology

32

Who was blinded after assignment to interventions (e.g., participants, care providers, outcome assessors, data analysts)

33

Statistical methods used to compare groups for primary and secondary outcomes, including harms

34

The number of participants evaluated for potential enrolment, no. of participants excluded before randomisation with reasons like Declined to participate etc. mentioned in the flow diagram

35

No. of participants Randomly assigned to each group, Who received intervention as allocated in both the groups

36

Intervention and comparator as they were actually administered (e.g.who delivered the intervention/comparator, whether participants adhered, whether they were delivered as intended) mentioned

37

A table showing baseline demographic and clinical characteristics for each group

38

the no. of participants included in the analysis, result for each group, and the estimated effect size and its precision (such as 95% confidence interval) mentioned

39

All harms or unintended events in each group mentioned.

40

Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence mentioned

41

Trial limitations, addressing sources of potential bias, imprecision, generalisability, and, if relevant, multiplicity of analyses mentioned

Are you sure you want to leave the page?

If you leave the page, you will lose your game progress.